AbbVie Inc. financials

ABBV CIK 0001551152

Source: EDGAR filings · Built 2026-06-02T02:13:01Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Free Cash Flow 17.82B 17.83B 22.06B 24.25B 21.99B 16.79B
EBITDA 23.21B 17.52B 21.45B 26.58B 26.45B 17.83B
Working Capital -14.23B -13.17B -4.84B -1.07B -7.27B -4.49B
Net Debt 63.15B 62.49B 47.47B 54.99B 67.83B 78.61B
Gross Margin 19.73% 19.00% 15.83% 18.86% 18.80% 20.03%
Operating Margin 24.65% 16.22% 23.49% 31.21% 31.89% 24.81%
Net Margin 6.91% 7.59% 8.95% 20.39% 20.54% 10.08%
Return on Equity (ROE) -129.24% 128.66% 46.94% 68.60% 74.91% 35.30%
Return on Assets (ROA) 3.15% 3.17% 3.61% 8.53% 7.88% 3.07%
Current Ratio 0.67× 0.66× 0.87× 0.96× 0.79× 0.84×
Debt-to-Equity -20.91× 20.46× 5.82× 3.72× 5.03× 6.66×
Effective Tax Rate 35.83% -15.34% 22.03% 12.11% 11.09% -36.02%
Cash Conversion Ratio 4.50× 4.40× 4.70× 2.11× 1.97× 3.81×
Accruals Ratio -0.11× -0.11× -0.13× -0.09× -0.08× -0.09×
SBC % of Revenue 1.56% 1.62% 1.38% 1.16% 1.23% 1.64%
CapEx Coverage 15.68× 19.31× 29.39× 35.89× 28.94× 22.04×
Free Cash Flow Per Share $10.05 $10.06 $12.44 $13.64 $12.37 $10.04

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
P/E Trailing (Diluted) 96.82× 74.35× 56.97× 24.38× 20.99× 39.39×
P/FCF 22.74× 17.67× 12.45× 11.85× 10.94× 10.68×
FCF Yield 4.40% 5.66% 8.03% 8.44% 9.14% 9.37%
EV / EBITDA 20.82× 22.14× 15.38× 13.09× 11.80× 15.18×
P/S 6.87× 5.78× 5.20× 5.05× 4.34× 4.19×
P/B 97.89× 27.27× 16.99× 15.85× 14.69×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Revenue from Contract with Customer, Excluding Assessed Tax 61.16B 56.33B 54.32B 58.05B 56.20B 45.80B
Revenues 61.16B 56.33B 54.32B 58.05B 56.20B 45.80B
Cost of Goods and Services Sold 18.20B 16.90B 20.41B 17.41B 17.45B 15.39B
Gross Profit 12.07B 10.71B 8.60B 10.95B 10.57B 9.17B
Selling, General and Administrative Expense 14.01B 14.75B 12.87B 15.26B 12.35B 11.30B
Operating Income (Loss) 15.07B 9.14B 12.76B 18.12B 17.92B 11.36B
Income Tax Expense (Benefit) 2.36B -570.00M 1.38B 1.63B 1.44B -1.22B
Net Income (Loss) Attributable to Parent 4.23B 4.28B 4.86B 11.84B 11.54B 4.62B
Earnings Per Share, Basic $2.37 $2.40 $2.73 $6.65 $6.48 $2.73
Weighted Average Number of Shares Outstanding, Basic 1.77B 1.77B 1.77B 1.77B 1.77B 1.67B
Earnings Per Share, Diluted $2.36 $2.39 $2.72 $6.63 $6.45 $2.72
Weighted Average Number of Shares Outstanding, Diluted 1.77B 1.77B 1.77B 1.78B 1.78B 1.67B

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 5.23B 5.52B 12.81B 9.20B 9.75B 8.45B
Assets, Current 29.06B 25.58B 33.00B 28.46B 27.93B 24.17B
Assets 133.96B 135.16B 134.71B 138.81B 146.53B 150.56B
Long-term Debt 64.50B 66.84B 59.24B 63.13B 75.96B 84.95B
Liabilities, Current 43.29B 38.75B 37.84B 29.54B 35.19B 28.66B
Stockholders' Equity Attributable to Parent -3.27B 3.33B 10.36B 17.25B 15.41B 13.08B

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities 19.03B 18.81B 22.84B 24.94B 22.78B 17.59B
Payments to Acquire Property, Plant, and Equipment 1.21B 974.00M 777.00M 695.00M 787.00M 798.00M
Net Cash Provided by (Used in) Investing Activities -6.64B -20.82B -2.01B -623.00M -2.34B -37.56B
Payments for Repurchase of Common Stock 980.00M 1.71B 1.97B 1.49B 934.00M 978.00M
Payments of Dividends 11.66B 11.03B 10.54B 10.04B 9.26B 7.72B
Net Cash Provided by (Used in) Financing Activities -12.72B -5.21B -17.22B -24.80B -19.04B -11.50B

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (ABBV CIK 0001551152), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

AGIO

AGIOS PHARMACEUTICALS, INC.

FONR

FONAR CORPORATION

PEB

PEBBLEBROOK HOTEL TRUST